Quote:

---

And lastly, after someone unavoidable delays, the pre-clinical study of leronlimab and a mouse model of glioblastoma at my father's lab at Einstein Montefiore Medical Center in New York, is now underway and we look forward to reviewing those results by the end of the year.

---

That was said on the 5/30/2024 Webcast

A Panoramic View

Quote:

---

ohm20 is thinking that Alzheimer's Disease trial takes place at Montefiore and from what Dr. Lalezari has said, it shall be "Cost-Effective". We already know that a murine study in GlioBlastoma Multiforme is happening at Montefiore thanks to Dr. Lalezari's dad, who happens to be a Neurosurgeon at Montefiore, who may be overseeing the GBM study.

"In October 2016, Parviz Lalezari, MD, Director, Neurological Surgery Research Laboratory, Montefiore, and Clinical Professor of Pathology and Neurological Surgery, Einstein, ...

He is currently engaged in research into Alzheimer’s disease and innovative cancer treatments."

He was 86 when this article was written and is 93 today. Despite his age, I'd suggest that between the GBM study and the Alzheimer's trial, Dr. Parviz Lalezari should have all the bases covered and questions answered regarding leronlimab's capacity of crossing the blood brain barrier, BBB. As a Neurosurgeon, Dr. Parviz Lalezari has removed GBM tumors from the brain of these hopelessly sick patients. He also, even at this age, counsels patients and their families on the hopes they can expect to have living with Alzheimer's Disease. It is the quest to find an answer to these neurological brain diseases that provides the motivation and impetus to fund and execute their programs using our drug which has kindled that hope for them again, now that the drug is finally off hold. They have been waiting in earnest. It is our hope that these trials and studies lead to much bigger, much larger trials, as in the development of a fully funded Phase III trial in Alzheimer's Disease and another fully funded Phase III trial for GBM.

It was just about 2 years ago when I put this post out on Alzheimer's so it is not farfetched to re-introduce Dr. Paul Edison where he too might be in some way involved, but Montefiore is definitely involved in GBM, but they, along with Dr. Edison could also be involved in Alzheimer's as well.

So, in the broad view, the strategy for Cost-Effectiveness is at the top of the Priority list. Glioblastoma Multiforme murine study shall be low cost. Alzheimer's trial should be completely funded "very soon". By whom? In which form? Monotherapy? Combination therapy? Maybe some of you smart guys and gals can throw in some possibilities .

---

The reddit has links.

Why GBM?

In addition, Scott Kelly alluded to the Albert Einstein murine GBM study and he indicated there will likely be future trials if this one is successful.

3/31/2022 Conference Call

Quote:

---

Scott Kelly 12:45: We've been contacted by academic institutions interested in doing studies with LL. A researcher from a top university in Boston. CAR T research. CAR T not working as well against solid tumors as was hoped. For this study we will need to supply molecule only, (they will do trial). It is believed that the tumor micro environment is contributing to the lack of effectiveness of CAR T progress against solid tumors and we can control the tumor micro environment we may be able to enhance the effectiveness of CAR T Therapy.

We have been contacted by the department of neurological surgery at a major academic center in NYC. and they are planning to evaluate LL in glioblastoma multiforme which is a very aggressive brain tumor. Again, we will supply LL and they've expressed their interest that if successful, in this non-clinical model, that they would pay for a human trial.

In the study in the use of check point inhibitors, which is funded by CytoDyn, it may represent another potential opportunity in immunotherapy and is moving forward.

We have been in contact in London with the university and foundation to further evaluate the potential of LL as a treatment in Alzheimer's. Their interest is in the role of neuro inflammation. It is similar to the role of cancer where initially people did not believe that cancer had an inflammatory component. I think the same is true in a number of central nervous system disorders.

We are also considering the potential of LL acting as a long acting HIV prep agent in macaques. If successful, we are very excited about this. This has the potential to turn LL into a once every 3 month injection from once per week. This could be future of HIV treatment with Prep as a long acting injectable.

Possibility of a grant funded Phase 2 clinical trail in LL with HIV patients with NASH & NAFLD, where we supply LL, but do not pay for the trial .

---